{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:27:42Z","timestamp":1755221262507,"version":"3.43.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Many studies were conducted to determine the association between genetic polymorphisms in CYP2B6 c.516G&gt;T and cyclophosphamide (CYC) efficacy or toxicity, no studies were focused on both clinical efficacy and toxicity of CYC. This study aimed to investigate the relationship between the CYP2B6 c.516G&gt;T polymorphism (rs 3745274) and 17 different parameters related to CYC efficacy and tolerability in Egyptian patients with lupus nephritis (LN).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A prospective cohort study on 142 LN patients with a mean age of 36.26 was conducted at Kasr Al Ainy School of Medicine, Cairo University, Egypt after the exclusion of 14 patients due to receiving an interacting medication with CYC. All clinical parameters related to CYC efficacy or toxicity were recorded and compared between the different genotypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There was a statistically significant difference between different genotypes in 11 out of 13 of the studied efficacy-related parameters. Many of the studied clinical parameters revealed that CYC\u2019s efficacy was associated with the presence of the T allele. There was a statistically significant difference between different genotypes in hepatotoxicity, diarrhea, and blood-related toxicities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>To our knowledge, this study is the first study that focused on studying 17 different parameters related to CYC efficacy and tolerability. Our findings paint a picture of the function that CYP2B6 polymorphisms play in Egyptian LN patients. Pre-treatment evaluation of CYP2B6 rs 3745274 may account for some individual differences in treatment response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000506","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T14:23:49Z","timestamp":1692800629000},"page":"172-180","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Genetic polymorphisms effect on cyclophosphamide\u2019s tolerability and clinical efficacy in Egyptian patients with lupus nephritis"],"prefix":"10.1097","volume":"33","author":[{"given":"Nermeen N.","family":"Abuelsoud","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Pharmacy, College of Pharmacy, Egyptian Russian University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engy M.","family":"EL Khateeb","sequence":"additional","affiliation":[{"name":"Department of Clinical and Chemical Pathology, Kasr Al Aini School of Medicine, Cairo University, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10067-020-05276-0","article-title":"Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis.","volume":"40","author":"Attia","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1586\/1744666X.2015.1087314","article-title":"Mycophenolate mofetil for lupus nephritis: an update.","volume":"11","author":"Mok","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome.","volume":"18","author":"Korbet","year":"2007","journal-title":"J Am Soc Nep"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"e0141979","DOI":"10.1371\/journal.pone.0141979","article-title":"Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation.","volume":"10","author":"El-Serafi","year":"2015","journal-title":"PLoS One"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","article-title":"Con: Cyclophosphamide for the treatment of lupus nephritis.","volume":"31","author":"Mok","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary.","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"e82562","DOI":"10.1371\/journal.pone.0082562","article-title":"Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.","volume":"8","author":"Preissner","year":"2013","journal-title":"PLoS One"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1","article-title":"Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.","volume":"41","author":"Mok","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nep.12136","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia.","volume":"19","author":"Mok","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis.","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2217\/pgs.09.134","article-title":"Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.","volume":"10","author":"Pinto","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2014.05.008","article-title":"Mismatch on glutathione s-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.","volume":"20","author":"Martinez-Bravo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbmt.2015.02.001","article-title":"Cytochrome P450 2B6*5 increases relapse after cyclophosphamide-containing conditioning and autologous transplantation for lymphoma.","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus.","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE.","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12272-014-0348-y","article-title":"Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations.","volume":"38","author":"Kim","year":"2014","journal-title":"Arch Pharm Res"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bcp.12800","article-title":"Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide\u2019s 4- hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.","volume":"81","author":"Shu","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.111.039586","article-title":"Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.","volume":"39","author":"Ariyoshi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"R23-20250808","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.","volume":"102","author":"Bray","year":"2010","journal-title":"Br J Cancer"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.31.4.398","article-title":"Functional characterization of cytochrome P4502B6 allelic variants.","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.tpj.6500157","article-title":"Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.","volume":"3","author":"Xie","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2005.08.008","article-title":"Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.","volume":"27","author":"Xie","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FPC.0b013e328045c4fb","article-title":"Genetic polymorphisms of CYP2B6 affect the pharmacokinetics\/pharmacodynamics of cyclophosphamide in Japanese cancer patients.","volume":"17","author":"Nakajima","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","article-title":"Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin\u2019s lymphoma.","volume":"55","author":"Veal","year":"2016","journal-title":"Eur J Cancer"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"1002959","DOI":"10.3389\/fimmu.2022.1002959","article-title":"Association between gene polymorphisms in cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.","volume":"13","author":"Mu\u00f1iz","year":"2022","journal-title":"Front Immunol"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2013-07-516666","article-title":"CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.","volume":"122","author":"Johnson","year":"2013","journal-title":"Blood"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"e0158890","DOI":"10.1371\/journal.pone.0158890","article-title":"CYP2B6rs2279343 is associated with improved survival of pediatric rhabdomyosarcoma treated with cyclophosphamide.","volume":"11","author":"Labib","year":"2016","journal-title":"PLoS One"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","article-title":"Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.","volume":"62","author":"Zhong","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R36-20250808","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.","volume":"23","author":"Rocha","year":"2009","journal-title":"Leukemia"},{"key":"R37-20250808","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases.","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur J Intern Med"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.30296","article-title":"Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.","volume":"63","author":"Le Guenno","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:00:15Z","timestamp":1754661615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000506","relation":{},"ISSN":["1744-6872"],"issn-type":[{"type":"print","value":"1744-6872"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}